Literature DB >> 21402228

[Pulmonary complications in adult sickle cell disease].

B Maître1, A Mekontso-Dessap, A Habibi, D Bachir, F Parent, B Godeau, F Galacteros.   

Abstract

Sickle cell disease is an autosomal genetic condition which represents the most frequent genetic disease in Île-de-France and Caribbean islands. The main clinical manifestations can be divided into infectious disease, hemolytic anemia and vaso-occlusive events. Pulmonary complications represent 20 to 30% of mortality due to sickle cell and can be divided into acute and chronic events. Acute chest syndrome (ACS) is an acute lung injury often preceded by a vaso-occlusive crisis and triggered by different factors including: hypoventilation, pulmonary infectious disease and vascular occlusions. These occlusions can be secondary to fat embolism, thrombosis or sickling. Treatment is mainly supportive combining oxygen supplementation adequate hydration analgesia and sedation. Exchange transfusion may be indicated in severe forms of ACS, characterized by a right ventricular dysfunction and acute respiratory failure. Pulmonary hypertension is the most serious chronic complication. Its frequency is estimated at 6% in adult patients and is more often described in patients with venous ulcers and higher levels of chronic hemolysis. Prognosis is poor with 12.5% of patients dying in the first two years following diagnosis irrespective of the actual pulmonary artery pressure level. There are currently limited data on the effects of any treatment modality. Other respiratory complications such as sleep disorders and nocturnal hypoxemia, infiltrative lung disease and exertional dyspnea are described and should be considered.
Copyright © 2011. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2011        PMID: 21402228     DOI: 10.1016/j.rmr.2010.08.013

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  4 in total

Review 1.  Cardiovascular abnormalities in sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev
Journal:  J Am Coll Cardiol       Date:  2012-03-27       Impact factor: 24.094

Review 2.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

3.  Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

Authors:  Claudia R Morris; Hae-Young Kim; Felicia Trachtenberg; John Wood; Charles T Quinn; Nancy Sweeters; Janet L Kwiatkowski; Alexis A Thompson; Patricia J Giardina; Jeanne Boudreaux; Nancy F Olivieri; John B Porter; Ellis J Neufeld; Elliott P Vichinsky
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

4.  Sickle cell disease activates peripheral blood mononuclear cells to induce cathepsins k and v activity in endothelial cells.

Authors:  Philip M Keegan; Sindhuja Surapaneni; Manu O Platt
Journal:  Anemia       Date:  2012-04-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.